Navigation Links
FDA Gives 510k Clearance to EyeKor’s EXCELSIOR™ Cloud-based Image Management Software for Ophthalmic Clinical Trials
Date:5/3/2013

DAVIS, CA and MADISON, WI (PRWEB) May 03, 2013

EyeKor, LLC, a new service provider dedicated to the support of ocular clinical trials, announces FDA 510k clearance of its EXCELSIOR™ image management software as a class 2 medical device, with indications for use specifically for managing ophthalmic clinical trial data. A first-of-its kind web application, EXCELSIOR™ employs a unique cloud-based architecture to enhance efficiency and accuracy in the collection and interpretation of data from ophthalmic clinical trials. EXCELSIOR™ provides a framework in which images from multiple imaging modalities can be reviewed and analyzed concurrently.

According to EyeKor CEO Christopher J. Murphy, DVM, PhD, “EXCELSIOR™ is unique: No other software leverages data from such a wide variety of ophthalmic instruments while providing such a transparent workflow and ease of access.”

Murphy continues: “EyeKor’s unique relationships with nationally recognized reading centers position it to support EXCELSIOR™ by harnessing the expertise of multiple reading centers with a broad range of functionalities.” These include fundus imaging, corneal imaging, visual field assessment, and electrophysiology—all of which can be viewed and assessed from within the unified EXCELSIOR™ platform.

EXCELSIOR™ provides investigators, clinical trial sponsors, and data managers secure, real-time access to their data and lets them follow its progress through each workflow stage—collection, quality analysis, grading, and interpretation—through a browser interface. The platform is supported by Reading Center trained staff and technicians, who provide certification, clinical site support, and quality analysis of the images—with all analysis and grading harmonized by the EXCELSIOR™ custom viewer that features image-enhancement tools specifically configured for ease of use.

From acquisition to final analysis, EXCELSIOR™ is uniquely designed to mee
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. U.S. Gives Green Light to Publish Controversial Bird Flu Research
2. Image share project gives patients and physicians anytime, anywhere access to medical images
3. Procedure gives patients with A-fib who cant take blood thinners alternative to reduce stroke
4. UMD team gives drug dropouts a second chance
5. FDA Panel Gives Blessing to New Weight-Loss Drug
6. Amazon Tribe Gives Clues to Heart-Healthy Lifestyles
7. Killer stainless steel: New process gives icon of cleanliness antibacterial coating
8. Aurora Dentist Gives Patients Big Savings With Teeth in a Day Implants
9. OC Firm Gives Back to Young Athletes
10. Study Gives First Evidence That Adult Human Lungs Can Regrow
11. FDA Gives Nod to New Breast Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... 25, 2014 Market Research ... Industry, 2009-2019 is a professional and in-depth ... Diagnostics industry. The report firstly reviews the ... classification, application and manufacturing technology. The report ... of Molecular Diagnostics listing their product specification, ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in ... after his combination drug therapy became too toxic. ... posted on the Surviving Mesothelioma website. , A ... Japan suggests that “maintenance therapy” with pemetrexed may be ... tolerate higher doses of cisplatin. , “Although the ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
... received a $1.5 million grant from the National Institutes ... major role in narcolepsy. ,Narcolepsy is a ... will further Yale research into narcolepsy and other disorders ... ,“The activity of these hypocretin cells is important ...
... a human tumor virus which causes Kaposi’s sarcoma and ... lymphomas with reported median survival time less than six ... of Helsinki have discovered that activation of the p53 ... lymphomas. ,The findings by the research group ...
... Center have found a new method for identifying suspect ... common acute infections in children. ,Traditionally, researchers ... down the virus or bacteria causing it. But that ... not be present in the blood or other easily ...
... to boycott the British Medical journal Lancet by a ... ‘warmongering’ attitude// of Lancet’s parent company Reed Elsevier. ... BMJ (formerly British Medical Journal) Fiona Godlee criticized that ... actually making money out of destroying health. ...
... conducted by Glenn Good and team from University of Missouri, ... of neurological injuries//. While it has been assumed all along ... study offers a new dimension to this issue. ... of their health. But the same quality is said to ...
... hospitals on the model of the All India Institute ... Bhubaneshwar, Jodhpur and Rishikesh under the Pradhan Mantri Swastha ... Welfare Anbumani Ramadoss has said. ,In a ... the Rajya Sabha, the upper House of the Indian ...
Cached Medicine News:Health News:$1.5 Million Grant to Yale for Narcolepsy-Neurotransmitter Study 2Health News:A Novel Treatment for KSHV-infected Lymphomas 2Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
... digital mobile imaging just got better ... and instrumentation. Now using,your C-arm you ... Easily Add Visualization and Navigation Technology, ... Intraoperative Decision Making, Provide a ...
... surgical navigation for Spine ... to integrate C-arm fluoroscopy ... It features automatic registration ... to the patient's anatomy, ...
... 20 years of CT engineering innovation and ... the forefront of the revolution in CT ... data at high speed with superb spatial ... extensive clinical experience and close cooperation with ...
... multislice CT scanners. In addition to the ... in an affordable Dual slice configuration. The ... advanced applications and high performance as the ... can be upgraded to Infinite Detector Technology, ...
Medicine Products: